Fast access to:
HIV-1 integrase drug resistance testing, Acanthamoeba educational information sheet, Human Identification Request Form and updated User Handbook.
Due to the increased use of integrase inhibitors (raltegravir, elvitegravir and dolutegravir) within HIV-1 treatment regimens, we have developed an assay to genotypically characterise resistance mutations relevant to this class of drugs. We are now able to offer integrase resistance testing for patients undergoing baseline screening or experiencing viral breakthrough on treatment, with a 5-day turn around time. We require a total volume of 0.5 ml of serum or plasma for HIV-1 resistance mutation assays. Please see new price lists for updated prices for this test.